Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Methodological issues in clinical trials of polycystic kidney disease: a focused review.

Journal of nephrology - 1 Jun 2017

Iliuta Ioan-Andrei, Kitchlu Abhijat, Pei York

Abstract excerpt

The field of therapeutics in autosomal dominant polycystic kidney disease (ADPKD) has seen a significant expansion recently, as major clinical trials have provided promising evidence in favor of new disease-modifying drugs. Though these trials are encouraging, limitations are noticeable in the form of methodological issues that restrict the interpretation of results. In this review, we discuss the methodological...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Patient Compliance
Share to Patient Selection
Share to Polycystic Kidney, Autosomal Dominant

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Randomized Controlled Trials as Topic

Share to Research Design

Share to Treatment Outcome

Share to TRPP Cation Channels

Share to Young Adult

Source

Identifiers

PMID: 27858251
DOI: 10.1007/s40620-016-0358-6

Genes

PKD1
PKD2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Methodological issues in clinical trials of polycystic kidney disease: a focused review.PMID 27858251Read ↗

Analysis of baseline parameters in the HALT polycystic kidney disease trials.Semantic proximity Read ↗

Investigational agents for autosomal dominant polycystic kidney disease: preclinical and early phase study insights.Semantic proximity Read ↗

GLP-1 receptor agonists in ADPKD: from metabolic rationale to phenotype-enriched translational testing.Semantic proximity Read ↗

Tolvaptan in ADPKD Beyond Trials: Tolerability, Monitoring, and Real-World OutcomesSemantic proximity Read ↗

Assessing disease modifying therapies in autosomal dominant polycystic kidney diseaseSemantic proximity Read ↗

Everolimus in Patients with Autosomal Dominant Polycystic Kidney DiseaseSemantic proximity Read ↗

Questioning the kidney-protective effects of tolvaptan: a testable hypothesis to revisit the current narrativeSemantic proximity Read ↗

Autosomal Dominant Tubulointerstitial Kidney Disease Clinical Trial Simulator: Case Reports of Model-Informed Drug Development.Semantic proximity Read ↗

Clinical trials for acute kidney injury: design challenges and possible solutions.Semantic proximity Read ↗

Long Residence Time at the Vasopressin V2 Receptor Translates into Superior Inhibitory Effects in Ex Vivo and In Vivo Models of Autosomal Dominant Polycystic Kidney DiseaseSemantic proximity Read ↗

Effect of tolvaptan on renal involvement in patients with autosomal dominant polycystic kidney disease according to different gene mutations.Semantic proximity Read ↗

The ENOS polymorphism is not associated with severity of renal disease in polycystic kidney disease 1.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.